Article
Pharmacogenetic assessment of tafenoquine efficacy in patients with Plasmodium vivax malaria.
Pharmacogenetics and genomics - 1 Sept 2020
St Jean Pamela L, Koh Gavin C K W, Breton John J, Espino Fe E J, Hien Tran T, Krudsood Srivicha, Lacerda Marcus V G, Llanos-Cuentas Alejandro, Lon Chanthap, Mohammed Rezika, Namaik-Larp Chayadol S, Pereira Dhelio B, Saunders David L, Velez Ivan D, Yilma Daniel, Villegas Maria F, Duparc Stephan, Green Justin A
Abstract excerpt
Plasmodium vivax has the largest geographic range of human malaria species and is challenging to manage and eradicate due to its ability to establish a dormant liver stage, the hypnozoite, which can reactivate leading to relapse. Until recently, the only treatment approved to kill hypnozoites was the 8-aminoquinoline, primaquine, requiring daily treatment for 14 days. Tafenoquine, an 8-aminoquinoline single-dose...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.